Odds ratio
Another way of comparing how likely something is between two groups. Similar in meaning to relative risk when the event is uncommon.
Also called: odds
Related words relative risk confidence interval
Topics Research
Another way of comparing how likely something is between two groups. Similar in meaning to relative risk when the event is uncommon.
Also called: odds
Related words relative risk confidence interval
Topics Research
Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.
Topics About Crohn's disease Cancer risk and screening Research
Jargon explained epidemiology prevalence hazard ratio all-cause mortality
A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.
Topics Surgery Biologics and newer medicines
Jargon explained retrospective hazard ratio immunomodulator
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics Biologics and newer medicines Research
Jargon explained head-to-head trial biologic-naive confidence interval
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics Biologics and newer medicines Research
Jargon explained network meta-analysis relative risk number needed to treat biosimilar